Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

AstraZeneca Announced Enhertu Showed Clinically Meaningful And Durable Responses Across Multiple HER2-Expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial

By Charles Gross
March 6, 5:52 AM
Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pretreated patients.

AZN

Read More
1 minute read

Lumos Pharma Announced Oral Presentation Highlighting Data On 15 Subjects From OraGrowtH212 Trial Supportive Of Conclusions From Interim Data Analysis

By Charles Gross
March 5, 3:46 PM
Lumos Pharma, Inc. (NASDAQ: LUMO) announced today that additional data from its OraGrowtH212 trial was included in an oral presentation of interim results at the 2023 International Meeting of Pediatric Endocrinology (IMPE), held in Buenos Aires, Argentina, March 4-7, 2023.

LUMO

Read More
1 minute read

Johnson & Johnson Unit Janssen Announced New VOYAGER PAD Analysis Confirms Consistent Benefit Of XARELTO Plus Aspirin Following Lower Extremity Revascularization

By Charles Gross
March 5, 12:13 PM
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following

JNJ

Read More
1 minute read

Abbott Labs Announced New Five-year Data Presented At American College Of Cardiology Scientific Sessions And Simultaneously Published In The New England Journal Of Medicine Reinforce The Long-term Safety And Effectiveness Of Mitraclip For Treating Seco…

By Charles Gross
March 5, 12:05 PM
Abbott (NYSE: ABT) today announced late-breaking data for MitraClip™, the leading therapy to treat leaky valves in people with mitral regurgitation (MR), that demonstrate long-term benefits of the device in patients battling heart failure.

ABT

Read More
1 minute read

Amarin Announced New REDUCE-IT Data Showing Benefit Of VASCEPA/VAZKEPA In High-Risk Patients With A Recent Acute Coronary Syndrome Event

By Charles Gross
March 5, 12:03 PM
Amarin Corporation plc (NASDAQ: AMRN) today announced a new analysis from the VASCEPA/VAZKEPA (icosapent ethyl) cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome (<12 months before randomization).

AMRN